Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal

This article was originally published in The Pink Sheet Daily

Executive Summary

Grounds for review include procedural issues, irrationality and human rights, according to Eisai.

You may also be interested in...



Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time

Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.

Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time

Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.

U.K. Court Upholds NICE Guidance On Alzheimer’s Drugs

Judge finds in favor of agency in five claims brought by Eisai but directs NICE to clarify advice for people with learning disabilities and whose first language is not English.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel